



Title	Cas9-guided haplotyping of three truncation variants in autosomal recessive disease
Author(s)	Natsuga, Ken; Furuta, Yoshikazu; Takashima, Shota; Nohara, Takuma; Huang, Hsin-Yu; Shinkuma, Satoru; Nakamura, Hideki; Katsuda, Yousuke; Higashi, Hideaki; Hsu, Chao-Kai; Fukushima, Satoshi; Ujiie, Hideyuki
Citation	Human mutation, 43(7), 877-881 <a href="https://doi.org/10.1002/humu.24385">https://doi.org/10.1002/humu.24385</a>
Issue Date	2022-07
Doc URL	<a href="http://hdl.handle.net/2115/90104">http://hdl.handle.net/2115/90104</a>
Rights	This is the peer reviewed version of the following article: Natsuga, K., Furuta, Y., Takashima, S., Nohara, T., Huang, H.-Y., Shinkuma, S., Nakamura, H., Katsuda, Y., Higashi, H., Hsu, C.-K., Fukushima, S., & Ujiie, H. (2022). Cas9-guided haplotyping of three truncation variants in autosomal recessive disease. Human Mutation, 43, 877– 881, which has been published in final form at 10.1002/humu.24385. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley 's version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Type	article (author version)
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	Supp_Mat.pdf (Supporting information)



[Instructions for use](#)

## **Supplementary Materials and Methods**

### **Transmission electron microscopy**

Skin samples were fixed in glutaraldehyde solution, post-fixed in 1% OsO<sub>4</sub>, dehydrated, and embedded in Epon 812. The embedded samples were sectioned at 1 μm thickness for light microscopy and thin-sectioned for electron microscopy (70 nm thick). The thin sections were stained with uranyl acetate and lead citrate and examined by transmission electron microscopy (H-7100; Hitachi, Tokyo, Japan).

### **Immunofluorescence**

Skin specimens were frozen on dry ice in an optimal cutting temperature (OCT) compound. Sections were incubated with primary antibodies, followed by FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, USA). The nuclei were stained with propidium iodide (PI). The stained immunofluorescent samples were then observed using a confocal laser scanning microscope FV-1000 (Olympus, Tokyo, Japan). The following primary mouse monoclonal antibodies were used: anti-laminin 332 (L332) (GB3; Sera-lab, Cambridge, UK), anti-type IV collagen (COL4) (PHM-12+CIV22;

NeoMarkers, Fremont, CA, USA), and anti-type VII collagen (COL7) (LH7.2; Sigma-Aldrich, St. Louis, MO, USA).

### **Whole exome sequencing**

gDNA was extracted from peripheral blood using QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) and sent for whole-exome sequencing to screen EB-related genes (Has et al., 2020; Uitto et al., 2018). Exome libraries were generated with SureSelect Human All Exon V6 (Agilent, Santa Clara, CA, USA) and sequenced with 100-bp paired-end sequencing on the NextSeq500 platform (Illumina, San Diego, CA, USA). Variant calling was performed with an in-house pipeline (Hou et al., 2021). The variants were filtered to retain those with a frequency of less than 0.05% in the 1,000 Genomes Project (<http://www.internationalgenome.org/>) and in the ExAC Browser (<http://exac.broadinstitute.org/>).

### **Sanger sequencing**

PCR amplification was performed on *COL7A1* exons that correspond to the proband's variants, followed by direct automated sequencing using an ABI

PRISM 3100 genetic analyzer (Applied Biosystems, Foster City, CA). The sequencing data were visualized by SnapGene Viewer (snapgene.com).

### **Guide RNAs (gRNAs)**

The gRNAs were assembled using CRISPR RNAs (crRNAs) and trans-activating crRNAs (IDT, Coralville, IA, USA). The crRNA probes were designed by the Benchling software (<https://benchling.com/academic>) (**Supplementary Table S5**).

### **nCATS**

Cas9 enrichment and adapter ligation of gDNA samples were performed as described previously (Gilpatrick et al., 2020; Natsuga et al., 2022), following the protocol for “Cas9 targeted sequencing” (ENR\_9084\_v109\_revP\_04Dec2018).

Briefly, gDNA was dephosphorylated by Quick Calf Intestinal Phosphatase (New England Biolabs). 1–3 µg of gDNA was applied to each reaction.

Cleavage and dA-tailing of dephosphorylated DNA samples were performed using Cas9 ribonucleoprotein complexes, dATP (New England Biolabs), and Taq polymerase (New England Biolabs) at 37 °C for 15 min. Cas9

ribonucleoprotein complexes were assembled with annealed all crRNAs/tracrRNA (IDT), CutSmart buffer (New England Biolabs), and *S. pyogenes* HiFi Cas9 nuclease (IDT). Adapter Mix (AMX) of Ligation Sequencing Kit SQK-LSK109 (Oxford Nanopore Technologies) was ligated to DNA ends using NEBNext Quick T4 Ligase (New England Biolabs) with Ligation buffer LNB of the Ligation Sequencing Kit (Oxford Nanopore Technologies). The samples were purified using AMPure XP beads (Beckman Coulter), used for library preparation, and applied to sequencing using MinION. For the analysis of the gDNA of the proband, a single reaction for each nCATS experiment (nCATS-1, nCATS-2, and nCATS-3) was prepared and pooled before purification using AMPure XP beads to apply for MinION sequencing as one library.

Reads were base called using Guppy v5.0.11 with dna\_r9.4.1\_450bps\_sup.cfg as a DNA model and were mapped to the genomic sequence of *COL7A1* (NC\_000003.12:c48595302-48564073) using minimap2 2.16-r922 (Li, 2017). Using SAMtools 1.9 (Li et al., 2009), information from the reads was mapped to the loci of the three variants and was extracted to generate a pileup output. For c.1474\_1505del, the allele on a read was

determined to be the deletion mutant when more than 80% of the corresponding sequence was deleted or determined to be wild-type if less than 20% was deleted. The threshold was based on the accuracy of MinION (90-99%) (Delahaye & Nicolas, 2021; Natsuga et al., 2022). Graphs were prepared using a GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Haplotypes with unexpected bases or indels at the variant loci were excluded from the graph.

## **Ethics**

The institutional review board of the Hokkaido University Graduate School of Medicine approved all human studies described above (ID: 13-043). The study was carried out according to the Declaration of Helsinki Principles. Participants or their legal guardians provided written informed consent.

## References to Supplementary Materials and Methods

Delahaye, C., & Nicolas, J. (2021). Sequencing DNA with nanopores: Troubles and biases. *PLoS One*, *16*(10), e0257521.

<https://doi.org/10.1371/journal.pone.0257521>

Gilpatrick, T., Lee, I., Graham, J. E., Raimondeau, E., Bowen, R., Heron, A.,

Downs, B., Sukumar, S., Sedlazeck, F. J., & Timp, W. (2020). Targeted nanopore sequencing with Cas9-guided adapter ligation. *Nat Biotechnol*,

*38*(4), 433-438. <https://doi.org/10.1038/s41587-020-0407-5>

Has, C., Bauer, J. W., Bodemer, C., Bolling, M. C., Bruckner-Tuderman, L.,

Diem, A., Fine, J. D., Heagerty, A., Hovnanian, A., Marinkovich, M. P.,

Martinez, A. E., McGrath, J. A., Moss, C., Murrell, D. F., Palisson, F.,

Schwieger-Briel, A., Sprecher, E., Tamai, K., Uitto, J., . . . Mellerio, J. E.

(2020). Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. *Br J Dermatol*, *183*(4), 614-627.

<https://doi.org/10.1111/bjd.18921>

Hou, P. C., Natsuga, K., Tu, W. T., Huang, H. Y., Chen, B., Chen, L. Y., Chen,

W. R., Hong, Y. K., Tang, Y. A., Lee, J. Y., Chen, P. C., Sun, H. S.,

McGrath, J. A., & Hsu, C. K. (2021). Complexity of Transcriptional and

Translational Interference of Laminin-332 Subunits in Junctional Epidermolysis Bullosa with LAMB3 Mutations. *Acta Derm Venereol*, 101(8), adv00522. <https://doi.org/10.2340/00015555-3874>

Li, H. (2017). Minimap2: pairwise alignment for nucleotide sequences.

arXiv:1708.01492. Retrieved August 01, 2017, from

<https://ui.adsabs.harvard.edu/abs/2017arXiv170801492L>

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,

Abecasis, G., Durbin, R., & Genome Project Data Processing, S. (2009).

The Sequence Alignment/Map format and SAMtools. *Bioinformatics*,

25(16), 2078-2079. <https://doi.org/10.1093/bioinformatics/btp352>

Natsuga, K., Furuta, Y., Takashima, S., Nohara, T., Kosumi, H., Mai, Y.,

Higashi, H., & Ujiie, H. (2022). Detection of revertant mosaicism in

epidermolysis bullosa through Cas9-targeted long-read sequencing. *Hum*

*Mutat*, 43(4), 529-536. <https://doi.org/10.1002/humu.24331>

Uitto, J., Bruckner-Tuderman, L., McGrath, J. A., Riedl, R., & Robinson, C.


(2018). EB2017-Progress in Epidermolysis Bullosa Research toward

Treatment and Cure. *J Invest Dermatol*, 138(5), 1010-1016.

<https://doi.org/10.1016/j.jid.2017.12.016>







**Supplementary Figure S1. COL7A1 variants detected in the family.**

The variant nomenclature is based on NM\_000094.4. The presence of variants

is indicated by arrows.

**Supplementary Table S1. Read counts of *COL7A1* haplotypes by nCATS-1.**

Sample	c.1474_1505del	c.2778_2779del	Reads
Proband	Mutant	Wild-type	90
	Wild-type	Mutant	90
	Wild-type	Wild-type	1
	Mutant	Mutant	0
	Others*		29
Total			210

\*Haplotypes with unexpected bases or indels at the loci.

**Supplementary Table S2. Read counts of *COL7A1* haplotypes by nCATS-2.**

Sample	c.2778_2779del	c.6781C>T	Reads
Proband	Mutant	Wild-type	42
	Wild-type	Mutant	38
	Wild-type	Wild-type	1
	Mutant	Mutant	1
	Others*		30
Total			112

\*Haplotypes with unexpected bases or indels at the loci.

**Supplementary Table S3. Read counts of *COL7A1* haplotypes by nCATS-3**

**(proband).**

Sample	c.1474_1505del	c.2778_2779del	c.6781C>T	Reads
Proband	Mutant	Wild-type	Mutant	9
	Mutant	Mutant	Wild-type	0
	Wild-type	Mutant	Mutant	0
	Mutant	Wild-type	Wild-type	1
	Wild-type	Mutant	Wild-type	16
	Wild-type	Wild-type	Mutant	0
	Mutant	Mutant	Mutant	0
	Wild-type	Wild-type	Wild-type	0
	Others*			17
<b>Total</b>				<b>43</b>

\*Haplotypes with unexpected bases or indels at the loci.

**Supplementary Table S4. Read counts of *COL7A1* haplotypes by nCATS-3**

**(mother).**

Sample	c.1474_1505del	c.6781C>T	Reads
Mother	Mutant	Wild-type	1
	Wild-type	Mutant	0
	Wild-type	Wild-type	22
	Mutant	Mutant	30
	Others*		4
Total			57

\*Haplotypes with unexpected bases or indels at the loci.

**Supplementary Table S5. The gRNA sequences and their target sites.**

gRNA name	gRNA sequence	Target site (GRCh38/hg38)	nCATS -1	nCATS -2	nCATS -3
COL7A1_c.147 4_fwd1	CCACTGGCTA CCGTGTGACA	Chr3:(-) 48592386	o		o
COL7A1_c.147 4_fwd2	TGTAGAGTCC TGAGTCTGCA	Chr3:(-) 48592301	o		o
COL7A1_c.147 4_fwd3	CTTGGAGCCA CCGCAGAAGG	Chr3:(-) 48591821	o		o
COL7A1_c.277 8_fwd1	GCTTCACGTG GTGCAGCGCG	Chr3:(-) 48588376		o	
COL7A1_c.277 8_fwd2	AGGAAGTTAG GGACCATTGG	Chr3:(-) 48588263		o	
COL7A1_c.277 8_fwd3	TGGGATCAAT GAGTTCATGG	Chr3:(-) 48588128		o	
COL7A1_c.277 9_rev1	CATCATGGGA GGTCATGCTG	Chr3:(+) 48587651	o		
COL7A1_c.277 9_rev2	AGTTCAATGC TTGGAACACG	Chr3:(+) 48587527	o		
COL7A1_c.277 9_ref3	GATCCCTGGA AGTGTCTGCG	Chr3:(+) 48587302	o		
COL7A1_c.678 1_rev1	ATGAAAGCTG AGGGTCATGA	Chr3:(+) 48572269		o	o
COL7A1_c.678 1_rev2	CAGAAAGATG AGACTCCGGA	Chr3:(+) 48572211		o	o
COL7A1_c.678 1_rev3	ATGTGGTGAG AAACAGACCA	Chr3:(+) 48571763		o	o